The quality of evidence was moderate for null associations with total cancer mortality and incident prostate cancer and low for null associations with mortality from colorectal, colon, rectal, lung, and gastric cancers and incidence of overall, colorectal, colon (total and distal), rectal, breast (total and ER+), bladder, and pancreatic cancers. Here, ESR1 is linked to prostate carcinoma.